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Background: Polyomavirus BK nephropathy (PyVAN) remains an important cause of early graft dysfunction and
graft loss in kidney transplantation.
Methods: In this retrospective, single centre cohort study we studied the incidence and outcome of BK viral
infection in 352 patients transplanted in 2008–2011.
Results: During follow-up viral replication was detected in 48 patients (13.6%); 22 patients (6.2%) had biopsy
proven PyVAN.
In multivariate logistic regression analyses risk factors for BK-viremia were lack of enrolment into randomized
controlled trials (RCTs), biopsy proven acute rejections, cytomegaly virus (CMV) serostatus of both donor and
recipient and previous transplantation.
In patients without PyVAN reduction or switch of immunosuppression was associated with rapid viral clearance and
stable graft function. In contrast, in most patients with PyVAN graft function deteriorated and 5 patients
prematurely lost their allograft. Switch of immunosuppression to a low dose cyclosporine plus mTOR inhibitor
based regimen in patients with PyVAN was safe, well tolerated and tended to be associated with a better
short-term outcome in terms of graft function compared to reduction of existing immunosuppression alone.
Conclusions: With the lack of licensed anti-polyoma viral drugs reduction or conversion of immunosuppression
remains the mainstay of therapy in patients with PyVAN. The combination of low dose cyclosporine plus mTOR
inhibition appears to be safe and warrants further investigation.
Keywords: Polyomavirus BK nephropathy, PyVAN, mTOR inhibitionBackground
Recent advances in transplant immunology have led to im-
proved allograft and patient survival following solid organ
transplantation. Biopsy-proven acute rejection rates in kid-
ney transplant recipients are now as low as ~10% [1,2].
While short-term outcome following kidney transplant-
ation is excellent, poor long-term allograft survival remains
an unmet issue. One downside of more potent immuno-
suppressive drugs is the rise of opportunistic infections that* Correspondence: johannes.jacobi@uk-erlangen.de
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reproduction in any medium, provided the ormay trigger premature graft failure. Of these, polyomavirus
nephropathy (PyVAN) has caught special attention within
recent years [3]. This virus, better known as BK virus be-
longs to the family of polyomaviridae, a group of small
double-stranded DNA viruses [4].
Inapparent spread of infection occurs early in childhood
and seroprevalence among the general population is high
(~80%) [5,6]. The virus has a specific tropism for the uro-
genital epithelium that represents a site of viral latency. BK
virus associated pathology primarily occurs in immuno-
compromised patients. Among solid organ transplant re-
cipients it is largely restricted to kidney transplantion. In
this group of patients the prevalence of viruria, viremiaLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is still under debate whether reactivation of latent BK virus
is host or donor-derived. Renal damage caused by BK virus
comprises progressive tubulointerstitial nephritis and ur-
eteral stenosis with a considerable risk of subsequent graft
failure in 15-50% of cases [8,9].
Known risk factors for the development of PyVAN are re-
cipient as well as donor age, recipient race (white) and gen-
der (male), HLA mismatches, previous biopsy proven acute
rejections (BPAR), type of immunosuppression (i.e. tacroli-
mus and mycophenolate mofetil), use of antilymphocyte
therapy and ureteral stent placement [10,11].
To date, there is no effective antiviral therapy against
PyVAN. The mainstay in the management of affected
patients is the reduction or conversion of triple im-
munosuppression [12]. Other treatment options include
the use of fluoroquinolones, intravenous immune
globulines, leflunomide or cidofovir. The lack of specific
targeted therapies has prompted a pre-emptive active
surveillance strategy with routine screening intervals
post transplantation for viral replication using PCR
assays [13].
In the present study we retrospectively analyzed the in-
cidence of BK viremia and PyVAN, the duration of viral
replication and the short term outcome following different
treatment strategies to achieve viral clearance.Methods
Study cohort
In this retrospective single centre cohort study all pa-
tients >18 years who received a renal allograft at the
University Clinic Erlangen during a four year period
(2008–2011) were included. Patients were referred for
transplantation from ~40 different non-profit or for-
profit dialysis centres.
Ureteral stents were placed in all patients for the first 6–
8 weeks after transplantation. Standard perioperative anti-
biotic regimen consisted of ampicillin/sulbactame for the
first 10 days. CMV prophylaxis was administered according
to current guidelines [13]. In all patients initial baseline
triple immunosuppression included a calcineurininhibitor
(CNI; either tacrolimus or CyA), antimetabolite (mycophe-
nolate-sodium or mycophenolate mofetil) and steroids.
All patients gave their written informed consent for data
collection and analysis prior to transplantation. All data
were collected in strictly pseudonymous form.
Based on the retrospective nature of this cohort study
and the fact, that patients were switched from one ap-
proved immunosuppressive regimen to another, this in-
ternal treatment guideline was not reviewed by our local
ethics committee. However, all patients as well as out-
side treating physicians were informed about the pur-
pose of reduction or conversion of immunosuppression.BK-screening and management of BK viremia and PyVAN
In all patients screening for BK viremia was recommended
at 3, 6, 9 and 12 months post transplantation. At months
3 and 12 blood samples were obtained while patients were
undergoing recommended protocol biopsies, at the re-
maining time points samples were collected in our out-
patient clinic. All transplant biopsies were stained for SV40
antigen and analyzed according to Banff criteria [14]. All
patients with documented BK viremia underwent add-
itional transplant biopsies at the time of diagnosis of viral
replication to confirm or rule out the presence of PyVAN.
In these patients follow-up biopsies were performed at the
discretion of the treating physician. In patients with BK
viremia viral load was measured every 6–8 weeks until at
least two blood samples were negative for BK.
Viral replication was detected by real time PCR with se-
quences of probes and primers chosen from conserved re-
gions of the BK virus (capsid and T-antigen) genome as
previously described [15]. The cut-off for this assay is 500
copies/ml.
In the presence of BK viremia the following treatment
options are advocated in our transplant centre. In patients
with low level viremia (103-104 copies/ml) without histo-
logical evidence for PyVAN, reduction of baseline im-
munosuppression (CNI 30% and mycophenolate mofetil
50%) is recommended. In cases of low immunological risk
or further rise of viremia despite reduction of immuno-
suppression, these patients are switched to a low CyA (C0
level: 60-80 ng/ml) plus mTORi (trough level: 5-8 ng/ml)
based immunosuppressive regimen at the discretion of the
treating physician. All patients with biopsy proven PyVAN
and viral replication >104 copies/ml are switched to a low
CyA plus mTORi based regimen as described above, when-
ever feasible. In patients with high immunological risk (high
levels of panel reactive antibodies, donor specific anti-
bodies, antibody mediated or severe cellular rejection epi-
sodes prior to the onset of BK viremia) and in patients with
eGFR <20 ml/min and/or proteinuria >1.0 g/g creatinine
reduction of current immunosuppression or switch of im-
munosuppression to a regimen other than low CyA plus
mTORi is recommended.
Statistical analysis
Data (all biopsy results and relevant laboratory data within
the first year) were collected and analysed using SPSS
(Version 18.0). Continuous variables were summarized
using descriptive statistics. Categorial variables were sum-
marized using frequency tables and analyzed using Chi-
Square test. Unpaired t-test or one-way ANOVA with
posthoc Bonferroni adjustment was applied for subgroup
analyses. Univariate and multivariate logistic regression
analyses were performed to identify determinants and pre-
dictors for BK viremia in transplant recipients. Bar graph
figures and results within the text are given as mean ± SD.
Jacobi et al. BMC Nephrology 2013, 14:207 Page 3 of 13




A total of 352 transplantations were included. Of these,
269 (76%) were deceased donor transplants (n = 198 recip-
ients ≤65 years, n = 71 recipients >65 years) and 83
(~24%) living donor transplants (n = 61 AB0-compatible,
n = 22 AB0-incompatible). In 22 patients simultaneous
pancreas-kidney (SPK) transplantation was performed.
In 9 recipients >65 years with expanded criteria donors
transplantation of two kidneys was performed. Mean
follow-up was 22.2 ± 13.9 months and did not differ be-
tween different subgroups treated for BK viral infection.
Death censored one year allograft survival was 92.9%,
patient survival at one year was 96.6%. Seven patients
died with a functioning graft, another five patients died
after having lost or without ever having graft function.
Baseline characteristics and transplant relevant data
of the entire study cohort, subgroups as well as pa-
tients with and without BK viremia are shown in
Tables 1 and 2.
Transplant biopsies and BPAR within the first year after
transplantation
Within the first year 1218 transplant biopsies (including
zero-hour biopsies) were performed. At 3 months 262
patients (74.4%) underwent transplant biopsies, 67 biop-
sies were done for indication. The overall rate of BPAR
at 3 months was 17.2% and significantly differed between
patients with protocol biopsies (12.3%) vs. biopsies done
for indication (31.3%, p = 0.001). At 12 months 188 pa-
tients (53.4%) underwent transplant biopsies. The overall
rate of BPAR at 12 months was 10.1% (n = 11 Banff IA,
n = 1 Banff IIA, n = 7 subclinical humoral rejection epi-
sodes with detection of donor specific antibodies).
Incidence, time course and risk factors for BK viremia and
PyVAN
During the study period BK viremia was detected in 48 pa-
tients (13.6% of the entire cohort, Figure 1A). Of these, 36
patients were male (15.5% of all males) and 12 patients
were female (10.0% of all females, p = n.s.). In 22 patients
(6.2% of the entire study cohort) renal biopsies confirmed
the presence of PyVAN (Figure 1A). The frequency of BK
viremia and PyVAN differed between subgroups, the
highest incidence was observed in recipients of deceased
donor allografts >65 years of age (Figure 1A).
Interestingly, all but one patient (preemptive trans-
plant recipient) with BK viremia were on hemodialysis
prior to transplantation (Table 1, p = 0.011). The use of
CNI, induction therapy and HLA-mismatch did not dif-
fer between patients with or without BK viral infection(Table 2). However, patients with BK viremia were sig-
nificantly older than patients without viral replication
(Table 1) while donor age was similar (Table 2).
Onset of BK viremia was noted after 182 ± 157 days,
or ~6 months after transplantation (see Additional file 1:
Table S1 and Figure 1B). In patients with biopsy proven
PyVAN the diagnosis of BK viremia was made later than
in individuals without histological evidence for BK ne-
phropathy (230 ± 189 vs. 141 ± 113 days, p = 0.050). In 31
of the 48 patients with BK infection (64.6%) onset of
viremia occurred between days 60–180 post transplant-
ation (months 3–6), in 2 patients (4.2%) viremia was
present before the third month after transplantation, in 3
patients (6.2%) with documented absence of viremia
within the first twelve months BK viremia occurred be-
tween days 529–775 post transplantation. The remaining
12 patients (25.0%) did not undergo routine screening for
viral replication as recommended (Figure 1B). In most of
these individuals diagnosis was made while patients were
admitted to undergo 1-year follow-up protocol biopsies.
On average, each patient underwent 2.8 PCR screen-
ings for BK viral replication within the first year. Of all
patients with at least one month graft survival 48
(14.4%) had no blood screening for BK viremia within
the first year. However, 33 of these patients had either
lost their allograft by month 3 (n = 5) or had a protocol
biopsy with absence of SV40 staining at this time point
(n = 28), so that the diagnostic coverage was complete.
Initial viral load of patients with BK viremia was
109.587 ± 245.821 copies/ml. Based upon the various
time points of detection of viral replication viral load in-
creased with time after transplantation (Figure 1B, p =
0.11). Overall, there was a significant correlation be-
tween time of onset of viremia following transplantation
and initial viral load (r = 0.34, p = 0.019, Figure 2A). In
patients with biopsy proven PyVAN initial and peak viral
loads were 1-log scale higher compared to patients with
BK viremia without histological evidence for PyVAN, but
significant overlap did not allow distinction. There was a
strong correlation between initial and peak viral load
(r = 0.84, p = 0.0008), overall viral replication did not dif-
fer between different treatment groups of patients with
either BK viremia or PyVAN (Figure 2B).
Using univariate logistic regression analyses the fol-
lowing variables were associated with BK viral replica-
tion (Table 3): ESP recipient status, recipient age, prior
biopsy proven acute rejections (BPAR), lack of partici-
pation in prospective clinical transplant trials, mode of
renal replacement therapy prior to transplantation, pre-
vious transplantation, donor (IgG -) as well as recipient
(IgG +) CMV-serostatus, LDL-cholesterol, and - with
borderline significance - 25-hydroxy vitamin D level.
Other known risk factors such as baseline CNI (tacroli-
mus), induction therapy or later use of ATG, HLA



















Age (years) 51.4 ± 13.5 48.7 ± 10.9 67.7 ± 2.7 43.0 ± 13.8 45.4 ± 11.5 0.0003 50.5 ± 13.4 56.9 ± 12.8 0.002
Sex (male/female) 232/120 133 / 65 51 / 20 35 / 26 13 / 9 n.s. 196 / 108 36 / 12 n.s.
BMI (kg/m2) 25.2 ± 3.9 24.8 ± 4.0 26.3 ± 3.9 24.9 ± 3.7 26.4 ± 3.4 0.013 25.2 ± 4.1 25.6 ± 3.1 n.s.
1st, 2nd, 3rd, 4th transplant 313 / 30 / 8 / 1 172 / 20 / 5 / 1 67 / 4 / 0 / 0 54 / 5 / 2 / 0 20 / 1 / 1 / 0 n.s. 274 / 24 / 6 / 0 39 / 6 / 2 / 1 0.035
Blood group (0, A, B, AB) 130 / 157 / 39 / 26 68 / 86 / 27 / 17 25 / 36 / 7 / 3 27 / 26 / 2 / 6 10 / 9 / 3 / 0 n.s. 108 / 137 / 37 / 22 22 / 20 / 2 / 4 n.s.
CMV IgG positive (n/%) 214 / 60.8 123 / 62.1 49 / 69.0 32 / 52.5 10 / 45.5 n.s. 178 / 58.6 36 / 75.0 0.020
Waiting time (months) 40.8 ± 36.4 58.2 ± 35.6 25.6 ± 25.9 10.3 ± 13.6 18.0 ± 24.9 0.0007 41.4 ± 36.8 36.9 ± 33.9 n.s.
Dialysis vintage (months) 54.2 ± 40.3 74.6 ± 37.4 39.1 ± 24.0 18.6 ± 24.2 18.5 ± 26.3 0.0003 54.8 ± 40.1 50.4 ± 41.7 n.s.
HD / PD / preemptive (n) 292 / 40 / 20 167 / 27 / 4 67 / 4 / 0 42 / 8 / 11 16 / 1 / 5 0.0001 245 / 40 / 19 47 / 0 / 1 0.011
Residual diuresis (ml/day) 614 ± 781 370 ± 616 625 ± 681 1178 ± 913 1200 ± 925 0.0005 627 ± 796 526 ± 680 n.s.
Systolic BP (mmHg) 140.1 ± 18.7 139.9 ± 19.6 143.9 ± 20.0 136.9 ± 15.5 138.7 ± 13.4 n.s. 140.5 ± 18.8 137.4 ± 18.1 n.s.
Diastolic BB (mmHg) 81.4 ± 10.8 81.8 ± 11.6 80.5 ± 9.8 81.5 ± 9.9 81.1 ± 9.1 n.s. 81.4 ± 11.0 81.3 ± 9.6 n.s.
Diabetes (n/%) 71 / 20.2 42 / 21.2 22 / 31.0 3 / 4.9 4 / 18.2 0.003 63 / 20.7 8 / 16.7 n.s.
CAD (n/%) 73 / 20.7 49 / 24.7 20 / 28.2 3 / 4.9 1 / 4.5 0.001 59 / 19.4 14 / 29.2 n.s.
CMV = cytomegaly virus, HD = hemodialysis, PD = peritoneal dialysis, BP = blood pressure, CAD = documented coronary artery disease.




































Donor age (years) 54.5 ± 14.0 48.3 ± 13.0 70.9 ± 5.7 55.9 ± 8.6 52.4 ± 8.4 0.0002 54.1 ± 13.8 56.8 ± 15.1 n.s.
Donor sex (male / female) 166 / 186 95 / 103 33 / 38 29 / 32 9 / 13 n.s. 146 / 158 20 / 28 n.s.
Donor BMI (kg/m2) 26.5 ± 4.5 26.6 ± 4.5 27.1 ± 5.5 26.2 ± 3.4 25.1 ± 3.2 n.s. 26.4 ± 4.3 27.4 ± 5.3 n.s.
Donor creatinine (mg/dl) 0.98 ± 0.62 1.03 ± 0.75 1.01 ± 0.53 0.81 ± 0.16 0.85 ± 0.12 n.s. 0.99 ± 0.65 0.91 ± 0.34 n.s.
Donor creatinine >1.5 mg/dl (n/%) 37 / 10.5 26 / 13.1 11 / 15.5 0 / 0 0 / 0 0.004 33 / 10.9 4 / 8.3 n.s.
Donor diuresis (ml/h) 156 ± 99 177 ± 106 158 ± 101 92 ± 24 108 ± 33 0.0005 158 ± 101 144 ± 82 n.s.
Cold ischemic time (h) 10.3 ± 5.8 13.3 ± 4.1 11.2 ± 3.9 2.2 ± 1.2 2.6 ± 1.1 0.0006 10.2 ± 5.8 10.7 ± 5.8 n.s.
HLA mismatch (n) 2.9 ± 1.7 2.4 ± 1.6 3.9 ± 1.2 3.4 ± 1.6 3.4 ± 1.3 0.0001 2.9 ± 1.6 2.9 ± 1.7 n.s.
Number of 0 mismatches (n/%) 41 / 11.6 38 / 19.2 1 / 1.4 2 / 3.3 0 / 0 0.0004 34 / 11.2 7 / 14.6 n.s.
Tacrolimus (n/%) 280 / 79.5 163 / 82.3 45 / 63.4 50 / 82.0 22 / 100 0.0005 242 / 79.6 37 / 77.1 n.s.
Cyclosporine (n/%) 72 / 20.5 35 / 17.7 26 / 36.6 11 / 18.0 0 / 0 0.0005 62 / 20.4 11 / 22.9 n.s.
ATG-induction (n/%) 65 / 18.5 48 / 24.2 8 / 11.3 7 / 11.5 2 / 9.1 0.018 57 / 18.7 8 / 16.7 n.s.
IL2-Induction (n/%) 280 / 79.5 145 / 73.3 61 / 85.9 54 / 88.5 20 / 90.9 0.010 241 / 79.3 39 / 81.2 n.s.
No induction (n/%) 7 / 2.0 5 / 2.5 2 / 2.8 0 / 0 0 / 0 n.s. 6 / 2.0 1 / 2.1 n.s.
Early steroid withdrawal (n/%) 46 / 13.1 30 / 15.1 12 / 16.9 4 / 6.6 0 / 0 n.s. 43 / 14.1 3 / 6.2 n.s.
PRAs (n/%) 45 / 12.8 34 / 17.2 6 / 8.4 4 / 6.6 1 / 4.5 0.044 36 / 11.8 9 / 18.7 n.s.
CMV risk profile (D-R-, D-R+, D+R+, D+R-)% 18/26/35/21 18/32/30/20 10/25/44/21 21/15/38/26 27/5/41/27 0.035 18/23/36/23 15/44/31/10 0.014
Study participant (n/%) 126 / 35.8 82 / 41.4 22 / 31.0 22 / 36.1 0 / 0 0.001 117 / 38.5 9 / 18.7 0.009
Primary function (n/%) 251 / 71.3 128 / 64.6 47 / 66.2 55 / 90.2 21 / 95.5 0.0006 216 / 71.1 35 / 72.9 n.s.
Creatinine at discharge (mg/dl) 2.04 ± 0.94 2.08 ± 0.98 2.40 ± 1.00 1.67 ± 0.69 1.56 ± 0.50 0.0001 2.00 ± 0.86 2.28 ± 1.33 0.057
eGFR at discharge (ml/min) 35.5 ± 14.7 35.1 ± 14.8 27.3 ± 9.8 43.1 ± 14.6 42.8 ± 13.1 0.0001 35.9 ± 14.7 33.3 ± 14.4 n.s.































































































Figure 1 Incidence of BK-viremia and PyVAN in the entire cohort and subgroups (Figure 1A). Time of onset of BK-viremia and
corresponding viral load (Figure 1B).
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http://www.biomedcentral.com/1471-2369/14/207mismatch, donor and recipient sex and donor age were
not associated with BK viremia.
All variables that were significant in univariate analyses
as well as the above mentioned known risk factors were
entered into the multivariate model. In the multivariate lo-
gistic regression analysis the following variables remained
significant predictors for BK viremia: lack of participation
in a prospective clinical transplant trial, BPAR, previous
transplantation, and donor (IgG-) as well as recipient
(IgG+) CMV-serostatus (Table 4).
Interestingly, patients who were enrolled into a pro-
spective clinical trial were less likely to develop BK viremia
(Table 2). Thus, the incidence of BK viremia was 17.3%
(39/226) in non-study participants and 7.1% (9/126) in pa-
tients recruited for a clinical trial (p = 0.009). Whereas the
frequency of induction therapy with ATG or basiliximab
did not differ between study versus non-study participants,
use of CyA as baseline CNI was more frequent in patients
enrolled into a clinical trial (38/126 or 30.2% vs. 35/226 or
15.5%, p = 0.002). More intriguingly, 36 of the 38 patients
initially treated with cyclosporine as baseline CNI wereenrolled into the HERAKLES trial (ClinicalTrials.gov
NCT00514514), a trial in which standard CNI therapy
with CyA was compared to a low dose CNI, or CNI free
immunosuppressive regimen. None of these 36 patients
developed BK viremia. Notably, screening intervals for BK
viral replication did not differ between study versus non-
study participants.
Patients with BK viremia were more likely to have a
prior episode of BPAR within the first year after trans-
plantation than patients with absence of viral replication
(39.6% vs. 23.0% BPAR within the first year, p = 0.014).
As previously shown by others, patients with previous
renal transplants had a higher incidence of BK viremia
(Table 1).
Donor (IgG-) and recipient (IgG+) CMV serostatus were
associated with BK viremia. The lowest incidence of BK
viremia was seen in high CMV risk patients (D+/R-: 5/76
or 6.6%), followed by low CMV risk patients (D-/R-: 7/62
or 11.3%). The highest incidence was noted in intermedi-
ate CMV risk patients (D+/R+: 15/123 or 12.2%; D-/R+: 21/






BK viremia: reduction of immunosuppression (n=15)
PyVAN: reduction of immunosuppression (n=7)
BK viremia: conversion other than low CyA + mTORi (n=4)
PyVAN: conversion other than low CyA + mTORi (n=2)
BK viremia: conversion low CyA + mTORi (n=7)




Figure 2 Scatterplot showing correlation between onset of BK-viremia and initial viral load (Figure 2A). Correlation of initial and peak
viral load in patients with BK viremia and PyVAN (open vs. grey symbols) under different treatment strategies (Figure 2B).
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http://www.biomedcentral.com/1471-2369/14/207During study follow-up 52 of 352 patients (14.8%) expe-
rienced CMV replication of at least 1000 copies/ml. The
incidence of CMV infection in patients with BK viremia
was 6/48 or 12.5%.Graft function and outcome of patients with BK Viremia
and PyVAN
During follow-up 5 of 48 patients (10.4%) with a history of
PyVAN lost their allograft. In three of these patients graft
loss was clearly related to PyVAN, another patient lost his
kidney due to ongoing antibody mediated rejection and
PyVAN. The fifth patient received an ECD kidney and de-
veloped low level viremia, graft loss occurred ~5 monthsTable 3 Univariate binary logistic regression analysis; variabl
Variable β S.
ESP recipient status (yes vs. no) 1.17 0.
Recipient age (per year) 0.040 0.0
BPAR (yes vs. no) 0.96 0.
Study participant (yes vs. no) −1.00 0.
Mode of RRT (vs. HD) −1.49 0.
Donor CMV IgG negative (yes vs. no) 0.70 0.
Previous transplantation (vs. first) 0.63 0.
Recipient CMV IgG positive (yes vs. no) 0.75 0.
LDL cholesterol (per mg/dl) 0.009 0.0
25-hydroxy vitamin D level (per nmol/l) 0.004 0.0
ESP = European Senior Program, BPAR = biopsy proven acute rejection, RRT = renaafter viral clearance and a final biopsy showed resolution of
PyVAN.
Duration of viral clearance was prolonged in patients
with PyVAN versus patients with BK viremia only (267
vs. 135 days, p = 0.018). A total of n = 5 patients still
have ongoing low level viremia (see Additional file 1:
Table S1).
In patients with negative screening for BK renal allograft
function improved within the first year after transplant-
ation whereas in patients with BK viremia and/or PyVAN
graft function did not improve during this time period
(Figure 3B). Within the 26 patients with BK viremia with-
out PyVAN treatment consisted of reduction of immuno-
suppression (n = 15), conversion to low CyA plus mTORies associated with BK viremia
E. OR 95% CI p-value
33 3.23 1.70 – 6.16 0.0003
13 1.04 1.01 – 1.07 0.002
34 2.60 1.33 – 5.08 0.005
39 0.37 0.17 – 0.79 0.010
67 0.22 0.060 – 0.84 0.027
31 2.00 1.08 – 3.72 0.027
29 1.87 1.07 – 3.29 0.028
35 2.12 1.06 – 4.24 0.033
04 1.009 1.000 – 1.018 0.041
02 1.004 1.000 – 1.009 0.050
l replacement therapy, OR = odds ratio, CI = confidence interval.
Table 4 Multivariate logistic regression analysis; predictors of BK viremia
Variable β S.E. OR 95% CI p-value
Study participant (yes vs. no) −1.82 0.56 0.16 0.054 – 0.49 0.001
BPAR (yes vs. no) 1.33 0.47 3.79 1.50 – 9.58 0.005
Donor CMV IgG negative (yes vs. no) 1.00 0.45 2.71 1.13 – 6.51 0.026
Recipient CMV IgG positive (yes vs. no) 1.05 0.49 2.84 1.10 – 7.37 0.031
Previous transplantation (vs. first) 1.009 0.49 2.74 1.05 – 7.15 0.039
For multivariate analyses all parameters that were significant in the univariate logistic regression model as well as the following known risk factors for BK viremia
that were negative in the univariate approach were entered into the model: recipient as well as donor sex, donor age, use of CNI (tacrolimus or CyA), ATG,
HLA mismatch).
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http://www.biomedcentral.com/1471-2369/14/207(n = 7) or to other regimens (n = 4). Out of the 22 patients
with PyVAN the majority was converted to low CyA plus
mTORi (n = 13) or other regimes (n = 2), while the re-
mainder where treated with reduced doses of their original















































Figure 3 Donor/Recipient CMV risk profiles in patients with (grey bar
course at the time of discharge as well as 3 and 12 months after transplan
Figure 3B). Only patients with complete creatinine values at all time pointIn patients with BK viremia without PyVAN renal func-
tion remained stable within the first year after transplant-
ation irrespective of selected treatment (Figure 4A + B). In
contrast, in patients with PyVAN renal function deterio-
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s) and without BK-viremia (white bars, Figure 3A). Creatinine























end of viremia (n=24)
ongoing viremia (n=2)
at last visit
BK-viremia: reduction of immunosuppression (n=15)
BK-viremia: conversion other than low CyA + mTORi (n=4)
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end of viremia (n=17)
ongoing viremia (n=3)
start of dialysis (n=2)
at last visit
PyVAN: reduction of immunosuppression (n=7)
PyVAN: conversion other than low CyA + mTORi (n=2)
PyVAN: conversion low CyA + mTORi (n=13)
(A) (B)
(C) (D)
Figure 4 Individual and mean creatinine course of patients with BK-viremia under different treatment strategies (Figure 4A + B).
Individual and mean creatinine course of patients with PyVAN under different treatment strategies (Figure 4C + D).
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mTORi based regimen tended to be associated with a bet-
ter short-term renal outcome compared to patients treated
with reduction of existing immunosuppression. Duration
of viremia, peak viral load as well as change of creatinine
and albuminuria between onset and clearance of BK
viremia did not differ between the three treatment groups
(Figure 5A-D).
Overall, reduction or conversion of immunosuppression
was relatively safe and well tolerated. Three patients with
BK viremia but lack of PyVAN developed donor specific
antibodies with biopsy proven antibody mediated rejection
during follow-up. These patients were treated with rituxi-
mab and a series of immunoadsorption without relapse of
BK-viral infection. In two of these patients, in which im-
munosuppression had been initially reduced to overcome
BK viremia, dose adjustment of triple immunosuppressive
regimen was performed whereas the third patient that had
been switched to low dose CyA plus mTORi was converted
to tacrolimus plus mycophenolate mofetil.
During follow-up one patient treated with reduction
of immunosuppression to achieve viral clearance laterdied from sepsis due to pneumocystis pneumonia (see
Additional file 1: Table S1). Another patient treated
with a combination of tacrolimus and sirolimus devel-
oped severe Legionella pneumonia requiring intensive
care treatment.
Discussion
The novel findings of this retrospective cohort study in-
clude the identification of putative novel risk factors for
BK viral infection after kidney transplantation and the ana-
lysis of conversion to a low CyA plus mTORi based im-
munosuppressive regimen especially in patients with
biopsy proven PyVAN. To the best of our knowledge, the
latter observation, although mainly hypothesis generating
and seeking for confirmation in future clinical trials, has
not yet been addressed by others.
Overall, incidence rates of BK viremia (13.6%) and
PyVAN (6.2%) in our study were similar to previously
published data [7,16-18]. However, we observed a rather
high incidence of BK viremia and PyVAN especially in
old transplant recipients. Since both donor and recipient
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Figure 5 Duration of viremia under different treatment strategies (Figure 5A; * = 1 patient with ongoing low level viremia, † = three
patients transplanted in 2011 with ongoing low level viremia, ‡ = 2 patients started dialysis prior to viral clearance). Peak viral load
under different treatment strategies (Figure 5B). Change in serum creatinine between onset and clearance of BK viremia under different
treatment strategies (Figure 5C; * = patients with ongoing low level viremia; ‡ = 2 patients that commenced dialysis prior to viral clearance).
Change in albuminuria between onset and clearance of BK viremia under different treatment strategies (Figure 5D). Mean values are presented
above each symbol.
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ESP allograft recipients, although patients in this subgroup
were more likely to receive CyA as initial CNI for which
lower rates of BK viral infection have been reported in the
literature as compared to tacrolimus [19]. One explanation
for this discrepancy maybe the higher incidence of BPAR
observed in CyA treated patients in our study cohort. In
fact, BPAR emerged as a risk factor for BK viral infection
and vice versa. This fateful relationship reflects the current
dilemma in the management of patients that are at risk for
BPAR or BK viral infection.
Interestingly, the incidence of BK viremia in AB0-
incompatible living donation was lower than in AB0-
compatible transplantation, although others have reportedcontroversial findings [20,21]. We and others have re-
cently described plasma cell infiltrates in renal allografts of
patients with PyVAN suggesting that humoral immunity
may play a role in polyoma viral disease [22,23], and it is
intriguing to speculate that the use of rituximab may
modulate the risk for PyVAN. However, in our study nei-
ther the use of ATG or rituximab given within the first
year after transplantation was associated with BK viremia.
In line with this observation polyoma virus replication was
not associated with rituximab therapy in pediatric patients
with nephrotic syndrome [24].
In agreement with previous observations recipient age,
BPAR and previous transplantation emerged as strong risk
factors for BK viremia [25-27]. Other known risk factors
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CNI and induction therapy or later use of ATG were not
associated with a greater risk of BK viral infection in our
study cohort. In addition, to these known variables we
identified novel putative risk factors for BK viremia. Thus,
patients that were enrolled into a clinical transplant trial
were at markedly lower risk to develop BK viremia. The im-
pact of study participation most likely reflects a greater
focus on target levels of immunosuppression and to some
extent the greater use of CyA as initial CNI, although
the effect remained significant in multivariate analyses ac-
counting for baseline immunosuppression and recipient age.
Another striking observation was that both negative
donor and positive recipient serostatus for CMV emerged
as predictors for BK virus infection. Accordingly, the highest
incidence of BK viremia was observed in CMV seropositive
patients that received an allograft from a seronegative donor,
whereas the lowest incidence was seen in CMV high risk
patients, i.e. donor CMV seropositive and recipient CMV
seronegative. While co-infection of polyomavirus and cyto-
megalovirus have been reported in renal transplant recipi-
ents [28,29] and after stem cell transplantation [30], the
impact of recipient CMV seropositivity without evidence
of CMV viremia on polyomavirus infection is unknown.
However, in a study of 132 hematopoietic stem cell trans-
plant recipients a positive recipient CMV serostatus and
the underlying disease emerged as the only risk factors as-
sociated with BK viremia [31].
A negative donor serostatus for CMV was only associ-
ated with a markedly greater risk to develop BK infection if
allografts were transplanted into seropositive recipients.
Thus, D-R+ CMV serostatus may trigger an immune re-
sponse within the CMV naïve allograft that may predispose
to other opportunistic viral infections. This hypothesis
needs to be further investigated. Overall, the effect of CMV
serostatus on BK viral infection is unlikely a chance finding
and cannot be explained by the different usage of CMV
prophylaxis with valganciclovir given the low incidence of
BK in D-R- patients.
Another interesting finding was that all but one patient
with BK viremia were treated with hemodialysis prior to
transplantation. Since peritoneal dialysis and preemptive
patients only reflected 17% of the entire study cohort this
could indeed be a chance finding. Possible explanations
that may otherwise explain this observation could be an
altered immune system in patients treated with an extra-
corporeal renal replacement therapy and better preserved
residual diuresis in peritoneal dialysis and pre-emptive
transplant candidates.
Our strategy in the management of patients with BK
viremia and PyVAN, namely reduction or conversion of
immunosuppression resulted in a favourable outcome in
most patients. In patients with BK viremia without evi-
dence of PyVAN reduction of net immunsuppression ledto rapid viral clearance and conversion of immunosup-
pression offered no benefit. Switch of immunosuppression
to a low CyA plus mTORi based regimen in patients with
biopsy proven PyVAN was safe, well tolerated and non-
inferior to reduction of immunosuppression with respect
to short-term follow-up. To the best of our knowledge the
combination of low dose CyA and mTORi has not yet
been studied in a comparable size of patients.
However, the role of mTORi in the treatment of BK viral
infection has gained more attention within recent years.
Available data suggests that mTORi reduce the expression
of BK virus large T antigen and antigen-dependent T-cell
expansion in a dose dependent manner [32,33]. In line with
these observations renal transplant recipients treated with a
mTORi based immunosuppressive regimen display BK viral
infection rates at the lower end reported in the literature.
In a retrospective cohort of comparable size in which all
patients (n = 344) received sirolimus the incidence of BK
viremia was only 1.7% [34]. Until now mTORi has largely
been used as rescue therapy in patients in whom other
strategies were ineffective or failed [35-38].
Our study is limited due to its retrospective, single centre
design with lack of long-term follow-up. In addition, proto-
col biopsies and sampling of blood for BK viremia was not
consistently available for all patients. Therefore, our find-
ings of selected treatments to achieve viral clearance are
hypothesis generating and need confirmation in prospect-
ive clinical trials in which changes of immunosuppression
are not dictated by immunological risk. Nevertheless, our
data indicate that conversion of immunosuppression to a
low CNI plus mTORi based immunosuppressive regimen
is feasible and safe.
Conclusion
In conclusion, this retrospective cohort study highlights the
importance of active surveillance for BK viral replication fol-
lowing kidney transplantation especially in aged transplant
recipients. In addition to previously known risk factors, we
identified novel risk factors for BK viral infection that need
to be confirmed in future clinical trials. In patients with bi-
opsy proven PyVAN conversion of immunosuppression to a
low CyA / mTORi based regimen showed promising results
that warrant further investigation in future trials.Additional file
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